Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2466
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? ; volume:11 ; number:1 ; day:23 ; month:5 ; year:2011 ; pages:1-4 ; date:12.2011
BMC pulmonary medicine ; 11, Heft 1 (23.5.2011), 1-4, 12.2011
- Urheber
- Beteiligte Personen und Organisationen
-
Amsberg, Gunhild von
Baumann, Hans Jörg
Honecker, Friedemann
Kluge, Stefan
Bokemeyer, Carsten
Brümmendorf, Tim Henrik
Klose, Hans
SpringerLink (Online service)
- DOI
-
10.1186/1471-2466-11-30
- URN
-
urn:nbn:de:1111-2016071616702
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hennigs, Jan Kristoff
- Amsberg, Gunhild von
- Baumann, Hans Jörg
- Honecker, Friedemann
- Kluge, Stefan
- Bokemeyer, Carsten
- Brümmendorf, Tim Henrik
- Klose, Hans
- SpringerLink (Online service)
Ähnliche Objekte (12)
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice
Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition
Editorial: Targeting bruton tyrosine kinase
Pulmonary capillary pressure in pulmonary hypertension
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
Newer Tyrosine Kinase Inhibitors for CML
Pulmonary arterial hypertension in a patient treated with dasatinib: a case report
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice
Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition
Editorial: Targeting bruton tyrosine kinase
Pulmonary capillary pressure in pulmonary hypertension
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
Newer Tyrosine Kinase Inhibitors for CML
Pulmonary arterial hypertension in a patient treated with dasatinib: a case report
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice
Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition
Editorial: Targeting bruton tyrosine kinase
Pulmonary capillary pressure in pulmonary hypertension
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
Newer Tyrosine Kinase Inhibitors for CML
Pulmonary arterial hypertension in a patient treated with dasatinib: a case report
Targeting tumour microenvironment by tyrosine kinase inhibitor